Live Markets, Charts & Financial News

™E Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024 By Investing.com

0 6

Berlin-(Business):™E Pharma NV (Euronext Growth Paris: AL™E), A clinical-stage biotechnology company focused on developing novel therapies to treat cancer by targeting the tumor environ- ment (E™), today announced that an abstract including results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation at the European Society for Medical Oncology (ESMO) Congress Scheduled to be held in Barcelona, ​​Spain, from 13 to 17 September 2024.

The oral presentation will provide further analysis of dual NOX-A12 inhibition and bevacizumab in glioblastoma in the expansion arm of the GLORIA Phase 1/2 trial. The full abstract will be published online via the ESMO Congress website at 00:05 am CEST on Monday 9 September 2024. It will be available simultaneously on ™E-Pharma website.

Dual inhibition of angiogenesis after radiation in glioblastoma: results from the phase 1/2 GLORIA trial
Presenter: doctor. Frank A. Giordano, Head of the Department of Radiation Oncology, University Medical Center Mannheim, Germany
a class: Short Oral Session: Central Nervous System Tumors
Time and date: 08.30-8.35 AM CEST, Sunday 15 September 2024

About E Pharma™

™E-Pharma A clinical-stage company focused on developing novel therapies to treat the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor-environment (TEN) and cancer-immune cycle by breaking down tumor barriers to the immune system and preventing tumor repair.

for more information:
™E Pharma NV
Aram Mangasarian, Ph.D., CEO
Tel. +49 (0) 30 16637082 0
investors@tmepharma.com

Investor and Media Relations:
Life Science Consultants
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com

Newcap
Arthur Rowell
Tel. +33 (0) 1 44 71 00 15
arwell@newcap.fr

Source: ™E Pharma NV

Leave A Reply

Your email address will not be published.